{"id":"propizepine","rwe":[],"tags":[{"label":"propizepine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Antihypertensive Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Cholinergic Agents","category":"pharmacology"},{"label":"Cholinergic Antagonists","category":"pharmacology"},{"label":"Ganglionic Blockers","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Nicotinic Antagonists","category":"pharmacology"},{"label":"Peripheral Nervous System Agents","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":["NCT01945814","NCT01626703","NCT06155409","NCT05997121"],"aliases":[],"patents":[],"pricing":[],"allNames":"depressin","offLabel":[],"synonyms":["propizepine","propiezepine","propizepine hydrochloride","depressin","propizepine HCl"],"timeline":[],"approvals":[],"brandName":"Depressin","ecosystem":[],"mechanism":{"modality":"Small Molecule","drugClass":"propizepine","explanation":"Imagine your brain is a complex computer, and Depressin is a software update that tries to fix a specific problem. However, since its target and mechanism are unknown, it's like trying to fix a problem without knowing what's causing it. More research is needed to understand how it works and what it does.","oneSentence":"Depressin is thought to work by interacting with a specific target in the brain, although its exact mechanism is unknown.","technicalDetail":"Depressin's mechanism of action is currently unknown, and further studies are required to elucidate its pharmacological properties and potential therapeutic applications."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2301","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=PROPIZEPINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:27:09.580939","biosimilars":[],"competitors":[],"dataSources":[{"url":"https://clinicaltrials.gov","name":"ClinicalTrials.gov","fields":["trialDetails","trials"],"retrievedDate":"2026-04-07"},{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"propizepine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT01945814","phase":"Phase 1","title":"Allogeneic Multivirus - Directed Cytotoxic T Lymphocytes (CTL) Targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton)","status":"COMPLETED","sponsor":"Catherine Bollard","isPivotal":false,"enrollment":27,"indication":"EBV, CMV","completionDate":"2018-10-16"},{"nctId":"NCT01626703","phase":"NA","title":"","status":"COMPLETED","sponsor":"National Clinical Research Coordination Center, Seoul, Korea","isPivotal":false,"enrollment":86,"indication":"Depression, Screening","completionDate":"2013-03"},{"nctId":"NCT06155409","phase":"N/A","title":"Safety and Performance of the SpineVision Hexanium ACIF in the Treatment of Cervical Spine Degenerative Disc Disease in Skeletally Mature Patients - HEXANIUM ACIF Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"SPINEVISION SAS","isPivotal":false,"enrollment":148,"indication":"Intervertebral Disc Degeneration","completionDate":"2027-07-31"},{"nctId":"NCT05997121","phase":"N/A","title":"Safety and Performance of the Hexanium TLIF System in the Treatment of Skeletally Mature Patients Suffering From Degenerative Disc Disease - Hexanium TLIF Study","status":"RECRUITING","sponsor":"SPINEVISION SAS","isPivotal":false,"enrollment":187,"indication":"Intervertebral Disc Degeneration","completionDate":"2027-10-30"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"NDDF":"005939","UNII":"09B57945V9","CHEBI":"CHEBI:135250","INN_ID":"2470","UMLSCUI":"C0072207","ChEMBL_ID":"CHEMBL2104749","PUBCHEM_CID":"112029","SECONDARY_CAS_RN":"14559-79-6","MESH_DESCRIPTOR_UI":"D018738","MESH_SUPPLEMENTAL_RECORD_UI":"C003256"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Depressin (PROPIZEPINE) is a small molecule drug in the propizepine class, but its target and mechanism of action are unknown. It is not clear if it is FDA-approved or commercially available. There is limited information available on its pharmacokinetic properties, such as half-life and bioavailability. Depressin is not listed as an approved indication, and its commercial status is unclear. Further research is needed to understand its clinical use and safety profile.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}